红日药业：关于注射用甲磺酸萘莫司他获得药物临床试验批件的公告

Core Viewpoint - Hongri Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its injectable drug, Nemonoxacin Mesylate, indicating progress in its drug development pipeline [1] Group 1 - The company announced the receipt of the clinical trial approval notice on February 6 [1] - The approval is based on the review by the National Medical Products Administration, confirming that the drug meets the registration requirements [1] - The notice number for the clinical trial approval is 2026LP00325 [1]